Home LiteratureArticle Details
PMID: 15302686 Published · ppublish English Comparative Study Journal Article Research Support, Non-U.S. Gov't

Coupling of the human A1 adenosine receptor to different heterotrimeric G proteins: evidence for agonist-specific G protein activation.

British journal of pharmacology ·Vol. 143 ·No. 6 ·2004-11-00 ·Pages 705-14

Cordeaux Y, Ijzerman AP, Hill SJ

Abstract

The present study investigates the effect of varying ligand structure on the ability of agonists to activate guanine nucleotide-binding proteins of the Gi, Gs and Gq families via the A(1) adenosine receptor. In CHO cells expressing this receptor, inhibition or potentiation of forskolin-stimulated cAMP accumulation was used as an end point to measure the activation of Gi and, in Pertussis toxin (PTX)-treated cells, Gs, respectively. Stimulation of inositol phosphate accumulation in PTX-treated cells was used as an index of Gq activation. CPA (N(6)-cyclopentyladenosine), NECA (5'-N-ethyl-carboxyamidoadenosine) and eight analogues of these ligands presented a range of guanine nucleotide-binding protein (G-protein)-activating profiles. Some ligands could only activate Gi (e.g. 2'deoxyCPA), some primarily Gi and Gs (and only weakly Gq) (e.g. 3'deoxyCPA), highlighting the importance of the ribose hydroxyls in agonist activation of multiple G proteins. CHA (N(6)-cyclohexyladenosine) activated Gi, Gs and Gq, but was more efficacious than CPA in activating Gs. The NECA analogues 5'-N-cyclopropyl-carboxamidoadenosine, 5'-N-cyclobutyl-carboxamidoadenosine and 5'-N-cyclopentyl-carboxamidoadenosine (CPeCA) also activated all three G proteins, although their ability to activate Gs and Gq (relative to CPA) was reduced with increasing substituent size, such that CPeCA produced only a small stimulation (at 100 microM) at Gq, but was a full agonist, relative to CPA, at Gi and Gs. This study suggests that the A(1) adenosine receptor can adopt agonist-specific conformations, arising from small changes in ligand structure, which lead to the differential activation of Gi, Gs and Gq.

MeSH Terms
Adenosine A1 Receptor Agonists Adenosine-5'-(N-ethylcarboxamide)/analogs & derivatives,metabolism,pharmacology Animals CHO Cells Cricetinae Dose-Response Relationship, Drug Heterotrimeric GTP-Binding Proteins/agonists,metabolism Humans Protein Binding/drug effects,physiology Receptor, Adenosine A1/metabolism
Chemicals
Adenosine A1 Receptor Agonists Receptor, Adenosine A1 Adenosine-5'-(N-ethylcarboxamide) Heterotrimeric GTP-Binding Proteins
Authors & Affiliations
3 authors, click to expand affiliations / ORCID
Cordeaux Yolande
Institute of Cell Signalling, Medical School, University of Nottingham, Nottingham NG7 2UH.
Ijzerman Adriaan P
Hill Stephen J
References (43)
43 references, click to expand
  1. A1 adenosine receptors. Two amino acids are responsible for species differences in ligand recognition.
    J Biol Chem. 1994 Nov 11;269(45):27900-6 PMID: 7961722
  2. Agonist-specific coupling of a cloned Drosophila octopamine/tyramine receptor to multiple second messenger systems.
    EMBO J. 1994 Mar 15;13(6):1325-30 PMID: 8137817
  3. Identification of domains of the human A1 adenosine receptor that are important for binding receptor subtype-selective ligands using chimeric A1/A2a adenosine receptors.
    J Biol Chem. 1995 Sep 1;270(35):20485-90 PMID: 7657625
  4. Agonist-receptor efficacy. II. Agonist trafficking of receptor signals.
    Trends Pharmacol Sci. 1995 Jul;16(7):232-8 PMID: 7667897
  5. Molecular analysis of beta(2)-adrenoceptor coupling to G(s)-, G(i)-, and G(q)-proteins.
    Mol Pharmacol. 2000 Nov;58(5):954-66 PMID: 11040042
  6. Influence of receptor number on functional responses elicited by agonists acting at the human adenosine A(1) receptor: evidence for signaling pathway-dependent changes in agonist potency and relative intrinsic activity.
    Mol Pharmacol. 2000 Nov;58(5):1075-84 PMID: 11040056
  7. Agonist trafficking of G(i/o)-mediated alpha(2A)-adrenoceptor responses in HEL 92.1.7 cells.
    Br J Pharmacol. 2001 Apr;132(7):1477-84 PMID: 11264241
  8. Principles: extending the utility of [35S]GTP gamma S binding assays.
    Trends Pharmacol Sci. 2003 Feb;24(2):87-90 PMID: 12559773
  9. Characterization of a Ca2+ response to both UTP and ATP at human P2Y11 receptors: evidence for agonist-specific signaling.
    Mol Pharmacol. 2003 Jun;63(6):1356-63 PMID: 12761346
  10. Differential involvement of intracellular domains of the rat NTS1 neurotensin receptor in coupling to G proteins: a molecular basis for agonist-directed trafficking of receptor stimulus.
    Mol Pharmacol. 2003 Aug;64(2):421-9 PMID: 12869647
  11. Ligand-selective receptor conformations revisited: the promise and the problem.
    Trends Pharmacol Sci. 2003 Jul;24(7):346-54 PMID: 12871667
  12. Molecular mechanisms of ligand-receptor interactions in transmembrane domain V of the alpha2A-adrenoceptor.
    Br J Pharmacol. 2003 Sep;140(2):347-58 PMID: 12970108
  13. Relationship between the inhibition constant (K1) and the concentration of inhibitor which causes 50 per cent inhibition (I50) of an enzymatic reaction.
    Biochem Pharmacol. 1973 Dec 1;22(23):3099-108 PMID: 4202581
  14. A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding.
    Anal Biochem. 1976 May 7;72:248-54 PMID: 942051
  15. Ribose-modified adenosine analogues as potential partial agonists for the adenosine receptor.
    J Med Chem. 1995 Sep 29;38(20):4000-6 PMID: 7562934
  16. Investigation of the role of conserved serine residues in the long form of the rat D2 dopamine receptor using site-directed mutagenesis.
    J Neurochem. 1996 Jan;66(1):394-402 PMID: 8522980
  17. N6,C8-distributed adenosine derivatives as partial agonists for adenosine A1 receptors.
    J Med Chem. 1996 Mar 29;39(7):1463-71 PMID: 8691477
  18. Reconstitution of recombinant bovine A1 adenosine receptors in Sf9 cell membranes with recombinant G proteins of defined composition.
    Mol Pharmacol. 1996 Dec;50(6):1587-95 PMID: 8967981
  19. Site-directed mutagenesis of the human A1 adenosine receptor: influences of acidic and hydroxy residues in the first four transmembrane domains on ligand binding.
    Mol Pharmacol. 1996 Dec;50(6):1635-42 PMID: 8967987
  20. Selective inhibition of adenylyl cyclase by octopamine via a human cloned alpha 2A-adrenoceptor.
    Br J Pharmacol. 1997 Sep;122(2):191-8 PMID: 9313925
  21. 8-Alkylamino-substituted analogs of N6-cyclopentyladenosine are partial agonists for the cardiovascular adenosine A1 receptors in vivo.
    J Pharmacol Exp Ther. 1997 Nov;283(2):800-8 PMID: 9353401
  22. Differential A1 adenosine receptor reserve for two actions of adenosine on guinea pig atrial myocytes.
    Mol Pharmacol. 1997 Oct;52(4):683-91 PMID: 9380032
  23. Selectivity of action of 8-alkylamino analogues of N6-cyclopentyladenosine in vivo: haemodynamic versus anti-lipolytic responses in rats.
    Br J Pharmacol. 1998 Jun;124(3):607-18 PMID: 9647488
  24. Effector pathway-dependent relative efficacy at serotonin type 2A and 2C receptors: evidence for agonist-directed trafficking of receptor stimulus.
    Mol Pharmacol. 1998 Jul;54(1):94-104 PMID: 9658194
  25. Contribution of serine residues to constitutive and agonist-induced signaling via the D2S dopamine receptor: evidence for multiple, agonist-specific active conformations.
    Mol Pharmacol. 1998 Aug;54(2):435-44 PMID: 9687586
  26. Involvement of G-protein betagamma subunits in coupling the adenosine A1 receptor to phospholipase C in transfected CHO cells.
    Eur J Pharmacol. 1998 Aug 14;355(1):85-93 PMID: 9754942
  27. Receptors for purines and pyrimidines.
    Pharmacol Rev. 1998 Sep;50(3):413-92 PMID: 9755289
  28. Activation of various subtypes of G-protein alpha subunits by partial agonists of the adenosine A1 receptor.
    Biochem Pharmacol. 1998 Nov 15;56(10):1287-93 PMID: 9825727
  29. Dual activation and inhibition of adenylyl cyclase by cannabinoid receptor agonists: evidence for agonist-specific trafficking of intracellular responses.
    J Pharmacol Exp Ther. 1998 Dec;287(3):884-8 PMID: 9864268
  30. Identification of the adenine binding site of the human A1 adenosine receptor.
    J Biol Chem. 1999 Feb 5;274(6):3617-21 PMID: 9920910
  31. 5'-N-substituted carboxamidoadenosines as agonists for adenosine receptors.
    J Med Chem. 1999 Apr 22;42(8):1384-92 PMID: 10212124
  32. The effect of site-directed mutagenesis of two transmembrane serine residues on agonist-specific coupling of a cloned human alpha2A-adrenoceptor to adenylyl cyclase.
    Br J Pharmacol. 1999 Jun;127(4):877-86 PMID: 10433494
  33. Further delineation of the two binding sites (R*(n)) associated with tachykinin neurokinin-1 receptors using [3-Prolinomethionine(11)]SP analogues.
    J Biol Chem. 1999 Aug 20;274(34):23770-6 PMID: 10446137
  34. Protein measurement with the Folin phenol reagent.
    J Biol Chem. 1951 Nov;193(1):265-75 PMID: 14907713
  35. Agonist regulation of D(2) dopamine receptor/G protein interaction. Evidence for agonist selection of G protein subtype.
    J Biol Chem. 2001 Aug 3;276(31):28667-75 PMID: 11369753
  36. 2',3'-Dideoxy-N6-cyclohexyladenosine: an adenosine derivative with antagonist properties at adenosine receptors.
    Eur J Pharmacol. 1988 Oct 26;156(1):157-60 PMID: 3208837
  37. A single column method for the assay of adenylate cyclase.
    Anal Biochem. 1990 May 15;187(1):98-103 PMID: 2164795
  38. Contributions of conserved serine residues to the interactions of ligands with dopamine D2 receptors.
    J Neurochem. 1992 Aug;59(2):627-35 PMID: 1321233
  39. ATP and its metabolite adenosine act synergistically to mobilize intracellular calcium via the formation of inositol 1,4,5-trisphosphate in a smooth muscle cell line.
    J Biol Chem. 1992 Aug 15;267(23):16081-7 PMID: 1322890
  40. Cloning and functional characterization of a human A1 adenosine receptor.
    Biochem Biophys Res Commun. 1992 Sep 16;187(2):919-26 PMID: 1530647
  41. In vitro and in vivo pharmacological characterization of N6-cyclopentyl-9-methyladenine (N-0840): a selective, orally active A1 adenosine receptor antagonist.
    J Pharmacol Exp Ther. 1993 Apr;265(1):227-36 PMID: 8386236
  42. A threonine residue in the seventh transmembrane domain of the human A1 adenosine receptor mediates specific agonist binding.
    J Biol Chem. 1994 Jan 28;269(4):2373-6 PMID: 8300561
  43. Adenosine receptor subtypes: characterization and therapeutic regulation.
    Annu Rev Pharmacol Toxicol. 1995;35:581-606 PMID: 7598508
Article Info
Journal
British journal of pharmacology
Abbr.
Br J Pharmacol
ISSN
0007-1188
Published
2004-11-00
Epub
2004-00-09
Pages
705-14
Language
English
Region
England
NLM ID
7502536
PMCID
PMC1575922
Subset
IM
Analysis Services
Analysis Services

Contact

No. 2 Wenbo Road, Zhangqiu District, Jinan, Shandong

Qilu Normal University · Genelibs Bioinformatics Lab

750 Shunhua Rd, Jinan

2F, Bldg F, University Science Park

Tel: 0531-88819269

WeChat Official Account

Follow our WeChat subscription account for real-time updates and the latest in medical and biological research.


Business Email

E-mail: product@genelibs.com